Coronary Artery Disease

Clinical Trial Finder

Many patients with coronary artery disease are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Low-dose of Ticagrelor and Double Standard-dose Clopidogrel on Platelet Aggregation in Clopidogrel Resistance's Patients With Coronary Heart Disease

Conditions:   Coronary Artery Disease;   Clopidogrel, Poor Metabolism of
Interventions:   Drug: Clopidogrel;   Drug: ticagrelor
Sponsor:   First Affiliated Hospital of Harbin Medical University
Recruiting - verified February 2017

RESOLUTE ONYX Post-Approval Study

Condition:   Coronary Artery Disease
Interventions:   Device: Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System;   Device: Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
Sponsor:   Medtronic Vascular
Not yet recruiting - verified February 2017

Feasibility of Orbital Atherectomy System in Calcified Bifurcation Lesion

Condition:   Coronary Artery Disease
Intervention:   Procedure: Frequency domain optical coherence tomography
Sponsors:   Icahn School of Medicine at Mount Sinai;   Cardiovascular Systems Inc
Recruiting - verified February 2017

Screening for Glucose Metabolism Disorders in Cardiac Rehabilitation

Condition:   Diabetes
Intervention:  
Sponsor:   Centre Hospitalier Universitaire Dijon
Recruiting - verified February 2017

Revascularization in Patients Undergoing Transcatheter Aortic Valve Implantation

Conditions:   Coronary Artery Disease;   Aortic Valve Stenosis;   TAVI;   PCI
Intervention:   Procedure: PCI
Sponsors:   Rigshospitalet, Denmark;   Aarhus University Hospital;   Aalborg Universitetshospital;   Odense University Hospital;   Lund University Hospital;   Karolinska University Hospital;   Rikshospitalet University Hospital;   Haukeland University Hospital;   Helsinki University Central Hospital;   Tampere University Hospital;   Oulu University Hospital
Not yet recruiting - verified February 2017

Fractional Flow Reserve Fax Registry

Condition:   Coronary Artery Disease
Intervention:   Diagnostic Test: Fractional Flow Reserve Measurement
Sponsors:   University of Erlangen-Nürnberg Medical School;   Abbott Vascular
Not yet recruiting - verified February 2017

Diagnostic Accuracy to Detect Hemodynamically Significant Stenosis by Non-invasive SURECardio CT-FFR

Condition:   Coronary Artery Disease
Intervention:   Device: CT-FFR. CTA. FFR
Sponsor:   Toshiba Medical Systems Corporation, Japan
Completed - verified February 2017

Effect of Antithrombotic Theatment in Patients With Coronary Heart Disease Complicated With Atrial Fibrillation

Conditions:   Atrial Fibrillation;   Coronary Heart Disease
Intervention:  
Sponsor:   Henan Institute of Cardiovascular Epidemiology
Recruiting - verified February 2017

Implication of Cardiac Shock Wave Therapy on Coronary Heart Disease

Condition:   Cardiac Ischemia
Interventions:   Device: Cardiac shock wave therapy;   Other: Sham cardiac shock wave (Control group)
Sponsor:   Beijing Hospital
Recruiting - verified February 2017

Henry Ford Heart Score Randomized Trial: Rapid Discharge of Patients Evaluated for Possible Myocardial Infarction

Conditions:   Chest Pain;   Heart Attack;   Coronary Artery Disease
Intervention:   Other: Deferral of admission for stress test
Sponsor:   Henry Ford Health System
Completed - verified February 2017

APP-based Multifaceted Management After PCI

Condition:   Percutaneous Coronary Intervention
Intervention:   Other: APP-based multifaceted management
Sponsor:   Chinese Academy of Medical Sciences, Fuwai Hospital
Not yet recruiting - verified February 2017

System Delay and Clinical Outcome Among Chinese Patients With AMI Treated With Reperfusion Therapy (MOODY Study)

Condition:   Coronary Heart Disease
Intervention:   Procedure: Reperfusion
Sponsor:   Nanjing First Hospital, Nanjing Medical University
Enrolling by invitation - verified February 2017

Optimal Duration of Clopidogrel in Second-Generation Drug-Eluting Stents

Condition:   Ischemic Heart Disease
Interventions:   Drug: 6-month dual anti-platelet therapy;   Drug: 12-month dual anti-platelet therapy;   Device: Zotarolimus eluting stent;   Device: Biolimus eluting stent
Sponsor:   Gangnam Severance Hospital
Completed - verified February 2017

Myocardial Injury and Severe Pneumococcal Pneumonia

Conditions:   Pneumonia, Pneumococcal;   Myocardial Ischemia
Interventions:   Diagnostic Test: Echocardiography;   Diagnostic Test: Cardiac Magnetic resonance
Sponsor:   Alejandro Rodriguez Oviedo
Not yet recruiting - verified February 2017

Platelet Acetyl Coenzyme A Carboxylase Phosphorylation in Coronary Artery Disease

Conditions:   Coronary Artery Disease;   Acute Coronary Syndrome;   Coronary Thrombosis
Intervention:   Diagnostic Test: Platelet Acetyl Coenzyme A Carboxylase analysis in CAD
Sponsor:   Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Completed - verified February 2017

Diagnostic Accuracy of CT-FFR Compared to Invasive Coronar Angiography With Fractional Flow Reserve

Condition:   Coronary Disease
Interventions:   Diagnostic Test: CT-FFR;   Diagnostic Test: Stress echocardiography
Sponsors:   St. Olavs Hospital;   Norwegian University of Science and Technology
Recruiting - verified February 2017

Validation of a Predictive Model of Coronary Fractional Flow Reserve in Patients With Intermediate Coronary Stenosis

Condition:   Coronary Stenosis
Intervention:   Diagnostic Test: Fractional Flow Reserve
Sponsor:   National Heart Centre Singapore
Recruiting - verified February 2017

EROSION II: OCT Guided PPCI in STEMI

Condition:   STEMI - ST Elevation Myocardial Infarction
Intervention:  
Sponsor:   Harbin Medical University
Recruiting - verified February 2017

Efficacy of Dotarem® (Gd-DOTA) Versus Magnevist® (Gd-DTPA) for Late Gadolinium Enhancement Cardiac Magnetic Resonance

Conditions:   Coronary Artery Disease;   Cardiomyopathy
Interventions:   Drug: Dotarem® (Gd-DOTA);   Drug: Magnevist® (Gd-DTPA)
Sponsors:   Dipan Shah;   Guerbet
Enrolling by invitation - verified February 2017

TIII Over TI in Subjects With Myocardial Infarction

Condition:   NSTEMI - Non-ST Segment Elevation MI
Intervention:   Other: Non interventional study
Sponsor:   University of Cologne
Completed - verified February 2017

The Impact of Depression and/or Anxiety on PCI Patients

Conditions:   Acute Coronary Syndrome;   MAjor Depressive Disorder;   Generalized Anxiety Disorder
Intervention:   Other: antidepressive and anti-anxiety therapy
Sponsors:   First Affiliated Hospital Xi'an Jiaotong University;   Shaanxi Provincial People's Hospital;   Xi'an Central Hospital;   Baoji Central Hospital;   Baoji People's Hospital;   General Hospital of Ningxia Medical University;   The People's Hospital of Ningxia;   Wuzhong People's Hospital;   The First Hospital of Lanzhou University;   LanZhou University;   First Affiliated Hospital of Xinjiang Medical University;   the People's Hospital of Xinjiang Uygur Autonomous Region;   The First People's Hospital of Kashgar Erea;   the First Division Hospital of Xinjiang Production and Construction Corps
Not yet recruiting - verified December 2016

Effect of Exercise on Selected Anthropometric,Biochemical and Physiological Variables Among Hypertensive Patients

Condition:   Hypertension
Interventions:   Other: Aerobic exercise .;   Other: Resistance exercise;   Other: Aerobic and resistance exercise
Sponsor:   Mekelle University
Recruiting - verified February 2017

Effect of Amlodipine Versus Amlodipine Combined With Atorvastatin on the Coronary Vasospastic Angina

Condition:   Quality of Life
Interventions:   Drug: Caduet 10Mg-20Mg Tablet;   Drug: NorvasC® 10 mg Tablets
Sponsor:   Kosin University Gospel Hospital
Not yet recruiting - verified February 2017

Outcomes in UK ACS Patients Prescribed Ticagrelor

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   AstraZeneca
Completed - verified February 2017

Colchicine and Spironolactone in Patients With STEMI / SYNERGY Stent Registry

Condition:   ST Elevation Myocardial Infarction
Interventions:   Drug: Colchicine;   Drug: Spironolactone;   Device: SYNERGY Bioabsorbable Polymer Drug-Eluting Stent;   Drug: Colchicine-Placebo;   Drug: Spironolactone-Placebo
Sponsors:   Population Health Research Institute;   Canadian Institutes of Health Research (CIHR);   Boston Scientific Corporation
Not yet recruiting - verified February 2017

Comparing TR Band to Statseal in Conjunction With TR Band

Conditions:   Arterial Occlusion;   Angina Pectoris;   Cardiovascular Diseases;   Atherosclerosis;   Hematoma;   Anticoagulant-Induced Bleeding;   Coronary Artery Disease
Interventions:   Device: StatSeal;   Device: TR Band
Sponsor:   VA Long Beach Healthcare System
Not yet recruiting - verified February 2017

Adenovirus Vascular Endothelial Growth Factor D (AdvVEGF-D) Therapy for Treatment of Refractory Angina Pectoris

Conditions:   Refractory Angina Pectoris;   Gene Transfer;   Coronary Artery Disease
Interventions:   Drug: AdvVEGF-D;   Drug: Control Rx
Sponsors:   Kuopio University Hospital;   Queen Mary University of London;   University College, London;   Medizinische Universitaet Wien;   Servicio Madrileño de Salud, Madrid, Spain;   FinVector Vision Therapies Oy;   Śląski Uniwersytet Medyczny w Katowicach;   Rigshospitalet, Denmark;   Euram Limited
Not yet recruiting - verified January 2017

Heart Rate Variability as a Predictor of Ischemic Heart Disease

Condition:   Acute Coronary Syndrome
Intervention:   Other: Heart rate variability
Sponsor:   University of Iowa
Completed - verified February 2017

Comprehensive Treatment of Angina in Women With Microvascular Dysfunction

Conditions:   Angina Pectoris;   Coronary Microvascular Disease
Interventions:   Dietary Supplement: Diet;   Behavioral: Training;   Drug: Medication (with statin and ACE-inhibition)
Sponsors:   Bispebjerg Hospital;   University Hospital Bispebjerg and Frederiksberg;   Cambridge Weight Plan Limited
Recruiting - verified February 2017

Effects of Different Doses of Ticagrelor on Platelet Aggregation and Endothelial Function in Diabetic Patients With Stable Coronary Artery Disease

Condition:   Coronary Artery Disease
Interventions:   Drug: ticagrelor;   Drug: clopidogrel
Sponsor:   First Affiliated Hospital of Harbin Medical University
Recruiting - verified August 2016

Improving Sleep for Healthy Hearts

Conditions:   Insomnia;   Coronary Heart Disease
Interventions:   Behavioral: Go! to Sleep;   Behavioral: General Sleep Education
Sponsors:   Brigham and Women's Hospital;   The Cleveland Clinic
Completed - verified February 2017

MyoVista Measurements in Patients With Atherosclerosis and CAD

Conditions:   Coronary Artery Disease (CAD);   Atherosclerosis
Intervention:   Device: MyoVista
Sponsors:   Los Angeles Biomedical Research Institute;   Heart Test Laboratories Inc.
Recruiting - verified August 2016

Role of Podocan and Wnt Pathway Regulatory Molecules in Coronary Artery Disease

Condition:   Coronary Artery Disease
Intervention:  
Sponsors:   Bassett Healthcare;   Baylor University
Recruiting - verified February 2017

LEADERS FREE II: BioFreedom™ Pivotal Study

Conditions:   Acute Coronary Syndrome;   High Bleeding Risk
Interventions:   Device: BioFreedom™ Drug Coated Coronary Stent System;   Drug: Dual Antiplatelet Therapy
Sponsor:   Biosensors Europe SA
Recruiting - verified February 2017

Early Vascular Healing in Acute Coronary Syndrome Patients With Different Doses of Rosuvastatin

Condition:   Acute Coronary Syndrome
Interventions:   Drug: High dose Rosuvastatin;   Drug: Low dose Rosuvastatin
Sponsor:   Nanjing First Hospital, Nanjing Medical University
Recruiting - verified February 2017

Moderato System: A Double-Blind Randomized Trial

Conditions:   Hypertension Resistant to Conventional Therapy;   Bradycardia;   Atrioventricular Block
Interventions:   Device: BackBeat-PHC ON;   Device: BackBeat-PHC OFF
Sponsors:   BackBeat Medical Inc;   MGH Echo Core Lab;   MLM Medical Labs GmbH;   nabios GmbH
Recruiting - verified February 2017

Trhombus Aspiration in Hyperglycemic ST-elevation myocardiAl InfarcTIon

Condition:   Hyperglycemia
Intervention:   Device: percutaneous coronary intervention
Sponsor:   Second University of Naples
Completed - verified February 2017

Observational Study to Evaluate the Safety of DILATREND SR Cap. in Korean Patients With Essential Hypertension, Chronic Stable Angina and Congestive Heart Failure

Conditions:   Essential Hypertension;   Chronic Stable Angina;   Congestive Heart Failure
Intervention:  
Sponsor:   Chong Kun Dang Pharmaceutical
Enrolling by invitation - verified February 2017

Myocardial Protection With Phosphocreatine in High-RIsk Cardiac SurgEry Patients

Conditions:   Cardiac Surgical Procedures;   Heart Valve Prosthesis Implantation
Interventions:   Drug: Phosphocreatine sodium tetrahydrate after anaesthesia induction;   Drug: 5% Glucose after anaesthesia induction;   Drug: Phosphocreatine sodium tetrahydrate added to cardioplegia;   Drug: 5% Glucose;   Drug: Phosphocreatine sodium tetrahydrate after heart recovery;   Drug: 5% Glucose after heart recovery;   Drug: Phosphocreatine sodium tetrahydrate after ICU admission;   Drug: 5% Glucose after ICU admission
Sponsor:   Meshalkin Research Institute of Pathology of Circulation
Active, not recruiting - verified February 2017

COMBO-Stent in Patients on Chronic Anticoagulant Therapy (COSTA) COSTA-Bleed and COSTA-Outcome Trials

Conditions:   Stable Angina;   Unstable Angina;   STEMI;   NSTEMI;   Coronary Disease
Interventions:   Device: COMBO-Stent;   Drug: Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran;   Device: Any drug eluting stent oder bare metal sent;   Drug: ASA, Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran
Sponsors:   IHF GmbH - Institut für Herzinfarktforschung;   OrbusNeich
Withdrawn - verified February 2017

Observational Registry on Acute Coronary Syndromes in Campania

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   Federico II University
Not yet recruiting - verified February 2017

Coroflex ISAR 2000 Registry

Condition:   Coronary Artery Disease (CAD)
Intervention:   Device: stenting with the Coroflex ISAR sirolimus-eluting stent
Sponsors:   B. Braun Melsungen AG;   Charite University, Berlin, Germany
Active, not recruiting - verified February 2017

Optimizing Timing of CABG in Patients Presenting With ACS and Treated With Ticagrelor

Condition:   Coronary Artery Disease
Interventions:   Procedure: PRU guided CABG;   Procedure: CABG per standard of care;   Device: VerifyNow assay;   Drug: Ticagrelor
Sponsor:   St. Michael's Hospital, Toronto
Recruiting - verified February 2017

Adalimumab in Alleviating Inflammation in Patients With Axial Spondyloarthritis

Condition:   Ankylosing Spondyloarthritis
Interventions:   Drug: Adalimumab;   Other: PET/CT imaging
Sponsors:   Helsinki University;   AbbVie
Recruiting - verified February 2017

Supernormal Oxygen Delivery for Elderly Surgical Patients

Condition:   Femoral Fractures
Interventions:   Procedure: SV maximization;   Procedure: supernormal DO2
Sponsor:   Guangzhou First Municipal People’s Hospital
Recruiting - verified February 2017

Coronary Bifurcation Lesions Treated With Biguard Stent System

Condition:   Coronary Artery Disease
Interventions:   Device: Biguard sirolimus-eluting bifurcation stent system;   Device: Sirolimus-eluting stent system
Sponsor:   Nanjing First Hospital, Nanjing Medical University
Terminated - verified February 2017

Colchicine in Percutaneous Coronary Intervention

Conditions:   Coronary Artery Disease;   Acute Coronary Syndrome
Intervention:   Drug: Colchicine vs Placebo
Sponsors:   VA Office of Research and Development;   New York University School of Medicine
Recruiting - verified February 2017

Get Going: Accelerometer-Based Intervention to Promote Physical Activity in Frail Older Adults

Conditions:   Coronary Artery Disease;   Heart Failure
Interventions:   Behavioral: Intervention;   Behavioral: Control
Sponsors:   American College of Cardiology;   Alliance for Academic Internal Medicine
Recruiting - verified November 2016

"Me and My Heart" Study

Condition:   Acute Coronary Syndrome
Interventions:   Device: Active group with MEMS;   Device: Active group without MEMS;   Device: Control group with MEMS;   Device: Control group without MEMS
Sponsor:   AstraZeneca
Recruiting - verified February 2017

A Comparison of an Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent for Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Conditions:   Coronary Artery Disease;   Acute Coronary Syndrome
Interventions:   Device: Orsiro;   Device: Xience
Sponsors:   University Hospital Inselspital, Berne;   University of Lausanne Hospitals
Recruiting - verified February 2017

Peripheral Chemoreflex/Arterial Baroreflex Interaction in Patients With Electrical Carotid Sinus Stimulation

Condition:   Hypertension, Resistant to Conventional Therapy
Interventions:   Other: Hypoxia without dopamine;   Other: Hypoxia with dopamine;   Other: Hyperoxia without dopamine;   Other: Hyperoxia with dopamine
Sponsors:   Hannover Medical School;   Charite University, Berlin, Germany;   Vanderbilt University School of Medicine;   Mayo Clinic;   University of Bristol
Recruiting - verified February 2017

Epidemiological Study on the Safety of Aspirin in The Health Improvement Network (THIN)

Conditions:   Secondary Prevention;   Stroke;   Ischemic Heart Disease;   Coronary Heart Disease
Interventions:   Drug: Acetylsalicylic Acid (Asprin, BAYE4465);   Drug: Clopidogrel, Oral Anticoagulants, NSAIDs and SSRIs
Sponsor:   Bayer
Recruiting - verified February 2017

Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-142

Condition:   Coronary Artery Disease
Intervention:   Drug: Lumason
Sponsor:   Bracco Diagnostics, Inc
Recruiting - verified February 2017

Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-141

Condition:   Coronary Artery Disease
Intervention:   Drug: Lumason
Sponsor:   Bracco Diagnostics, Inc
Recruiting - verified February 2017

Assessing Diagnostic Value of Non-invasive FFRCT in Coronary Care

Condition:   Coronary Artery Disease
Intervention:  
Sponsor:   HeartFlow, Inc.
Enrolling by invitation - verified February 2017

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

Condition:   Acute Coronary Syndrome
Interventions:   Drug: dalcetrapib;   Drug: Placebo
Sponsors:   DalCor Pharmaceuticals;   The Montreal Health Innovations Coordinating Center (MHICC);   Medpace, Inc.;   Roche Molecular Systems, Inc
Recruiting - verified February 2017

Short-Term Dual Antiplatelet and Maintenance CloPidogrel Therapy After Drug-Eluting Stent Implantation

Condition:   Coronary Artery Disease
Interventions:   Drug: Clopidogrel;   Drug: Aspirin plus clopidogrel
Sponsors:   CHEOL WHAN LEE, M.D., Ph.D;   CardioVascular Research Foundation, Korea;   Medtronic;   Chong Kun Dang Pharmaceutical Corp.
Terminated - verified February 2017

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

Condition:   Peripheral Artery Disease
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban-Placebo
Sponsors:   Bayer;   Janssen Research & Development, LLC;   Colorado Prevention Center
Recruiting - verified February 2017

Medtronic RevElution Trial

Condition:   Coronary Artery Disease
Intervention:   Device: Polymer-free DES (Drug Eluting Stent)
Sponsor:   Medtronic Vascular
Active, not recruiting - verified February 2017

Korean Coronary Overlapping Stenting Registy

Condition:   Coronary Artery Disease
Intervention:  
Sponsor:   The Catholic University of Korea
Recruiting - verified February 2017

Mesenchymal Stem Cell Administration in the Treatment of Coronary Graft Disease in Heart Transplant Patients

Conditions:   Coronary Disease;   Heart Transplant
Intervention:   Biological: Mesenchymal cell therapy
Sponsor:   Assistance Publique - Hôpitaux de Paris
Suspended - verified February 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified February 2017

Stress Ulcer Prophylaxis in the Intensive Care Unit

Conditions:   Gastrointestinal Bleeding;   Stress Ulcers
Interventions:   Drug: Pantoprazole;   Other: Saline (0.9%)
Sponsors:   Dr. Morten Hylander Møller;   Rigshospitalet, Denmark;   Copenhagen Trial Unit, Center for Clinical Intervention Research
Recruiting - verified February 2017

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

Condition:   Acute Coronary Syndromes
Interventions:   Drug: Apixaban;   Drug: vitamin K antagonist;   Drug: Acetylsalicylic acid;   Other: Acetylsalicylic acid placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke Clinical Research Institute
Recruiting - verified February 2017

Saxagliptin and Acute Myocardial Infarction:Effects on Platelet Function

Condition:   Platelet Aggregation During Acute Myocardial Infarction
Interventions:   Drug: saxagliptin;   Drug: placebo
Sponsors:   University of Sao Paulo General Hospital;   InCor Heart Institute
Recruiting - verified January 2017

Comparison of Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients With Acute Coronary Syndromes

Condition:   Acute Coronary Syndrome
Interventions:   Drug: ticagrelor;   Drug: clopidogrel
Sponsors:   Seung-Jung Park;   AstraZeneca;   Roche Pharma AG;   KBM pharm
Active, not recruiting - verified February 2017

DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease

Condition:   Coronary Atherosclerosis
Intervention:  
Sponsors:   University of Surrey;   Ashford and St. Peter's NHS Trust
Completed - verified February 2017

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Acetylsalicylic acid;   Drug: Rivaroxaban;   Drug: Clopidogrel;   Drug: Ticagrelor
Sponsors:   Janssen Research & Development, LLC;   Bayer;   Duke Clinical Research Institute;   Harvard Medical School
Completed - verified February 2017

RuSsian RegisTry of Acute CoronaRy SyndromE TreAtMent and Approach in Dual Antiplatelet Therapy

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting - verified February 2017

Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial

Condition:   Cardiogenic Shock
Intervention:   Device: HeartMate PHP
Sponsors:   Thoratec Corporation;   St. Jude Medical
Terminated - verified February 2017

Real Life Long-term Adherence to Ticagrelor After PCI for Acute Coronary Syndromes

Condition:   Acute Coronary Syndrome (ACS)
Intervention:   Drug: Ticagrelor
Sponsor:   IHF GmbH - Institut für Herzinfarktforschung
Completed - verified February 2017

Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry

Condition:   Acute Coronary Syndromes
Intervention:   Other: Non-Interventional Study
Sponsor:   AstraZeneca
Recruiting - verified February 2017

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Conditions:   Stroke;   Secondary Prevention
Interventions:   Drug: optional ASA as comedication;   Drug: placebo to ASA;   Drug: placebo to optional ASA as comedication;   Drug: placebo to dabigatran etexilate;   Drug: ASA 100 mg;   Drug: dabigatran etexilate
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2017

A Trial of Low-dose Adjunctive alTeplase During prIMary PCI

Condition:   Myocardial Infarction
Interventions:   Drug: Alteplase;   Other: Placebo
Sponsors:   NHS Greater Glasgow and Clyde;   University of Glasgow;   National Institute for Health Research, United Kingdom
Recruiting - verified September 2016

Sleep and Stent Study: a Multicentre, Prospective Study

Condition:   Obstructive Sleep Apnea
Intervention:  
Sponsors:   National University, Singapore;   Boston Scientific Corporation
Completed - verified February 2017

Prospective, Single-arm, Multi Centre Observations Ultimaster Des Registry

Condition:   Coronary Artery Disease
Intervention:  
Sponsor:   Terumo Europe N.V.
Recruiting - verified July 2016

Efficacy and Safety of Implantable Cardioverter-Defibrillator (ICD) Implantation in the Elderly

Conditions:   Cardiomyopathy;   Coronary Artery Disease;   Congestive Heart Failure;   Myocardial Infarction
Interventions:   Device: Implantable Cardioverter Defibrillator;   Other: Optimal Medical Therapy
Sponsor:   VA Office of Research and Development
Recruiting - verified February 2017

A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Ticagrelor 60 mg;   Drug: Ticagrelor placebo
Sponsor:   AstraZeneca
Active, not recruiting - verified February 2017

Initial Human Validation of Simultaneous Dual-Tracer Cardiac PET Imaging

Conditions:   Ischemic Heart Disease;   Myocardial Infarction
Intervention:   Drug: Cardiac PET scan w/18F-Fluorodeoxyglucose and rubidium-82
Sponsor:   University of Michigan
Completed - verified February 2017

Improved Cardiovascular Risk Reduction to Enhance Rural Primary Care

Conditions:   Diabetes Mellitus;   Hypertension;   Coronary Artery Disease;   Atrial Fibrillation;   Stroke
Interventions:   Other: PHCVRS Intervention;   Other: Personal Health Record
Sponsor:   Barry L. Carter
Active, not recruiting - verified February 2017

Drug-eluting Stents vs. Drug-coated Balloon for Preventing Recurrent In-stent Restenosis

Condition:   Coronary Restenosis
Interventions:   Device: Everolimus-eluting balloon expandable stent;   Device: paclitaxel eluting balloon
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea
Terminated - verified February 2017

Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   AstraZeneca
Completed - verified February 2017

Intensive Prevention Program After Myocardial Infarction

Conditions:   Myocardial Infarction;   Prevention Harmful Effects
Interventions:   Behavioral: Intensive Prevention Program;   Other: Standard medical and interventional therapy
Sponsors:   Herzzentrum Bremen;   Oldenburger Forschungs- und Entwicklungsinstitut für Informatik (OFFIS).
Active, not recruiting - verified February 2017

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

Condition:   Prevention &Amp; Control
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin;   Drug: Aspirin placebo;   Drug: Rivaroxaban placebo;   Drug: Pantoprazole
Sponsors:   Bayer;   Hamilton Health Sciences Corporation, Population Health Research Institute;   Janssen Research & Development, LLC
Recruiting - verified February 2017

On-treatment PLAtelet Reactivity-guided Therapy Modification FOR ST-segment Elevation Myocardial Infarction

Condition:   Acute ST-elevation Myocardial Infarction
Intervention:   Drug: Antiplatelet Regimen Modification (aspirin or ticagrelor)
Sponsor:   Clinical Centre of Serbia
Recruiting - verified February 2017

Comparison of Rubidium PET and SPECT With CZT Crystals for Detection of Myocardial Ischemia in Overweighed Patients and Women

Condition:   Myocardial Ischemia
Intervention:   Radiation: Rubidium PET
Sponsor:   Assistance Publique - Hôpitaux de Paris
Completed - verified June 2016

LONG-DES VI (Drug Eluting Stent for Long Lesions in Coronary Artery)

Condition:   Coronary Artery Disease
Intervention:   Device: percutaneous coronary intervention
Sponsors:   Seung-Jung Park;   Abbott;   CardioVascular Research Foundation, Korea
Terminated - verified February 2017

CPR Training: Video Self-Instruction Kit or Video-Only

Conditions:   Cardiovascular Risk Factors;   Coronary Disease;   Cardiac Arrest
Interventions:   Other: CPR Training using the Family and Friends CPR Anytime Video Self Instruction;   Other: Implementation of a Hospital-based CPR Training Model;   Other: Follow-up prompting to encourage skill retention
Sponsor:   University of Pennsylvania
Active, not recruiting - verified February 2017

Prevention of Serious Adverse Events Following Angiography

Conditions:   Acute Renal Failure;   Kidney Disease;   Coronary Artery Disease
Interventions:   Drug: IV isotonic saline;   Drug: IV isotonic bicarbonate;   Drug: N-acetylcysteine;   Drug: Placebo
Sponsors:   VA Office of Research and Development;   The George Institute
Recruiting - verified February 2017

Venous Function in Cardiovascular Disease Patients

Condition:   Myocardial Infarction
Interventions:   Behavioral: interval training day 1;   Behavioral: Moderate exercise day 2;   Behavioral: Control day 3
Sponsor:   Norwegian University of Science and Technology
Completed - verified February 2017

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Condition:   Crohn's Disease
Interventions:   Drug: CP-690,550;   Drug: CP-690,550
Sponsor:   Pfizer
Completed - verified February 2017

Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease (FIMA-DEFER)

Condition:   Coronary Artery Disease
Interventions:   Drug: Fimasartan;   Drug: Placebo
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea;   Boryung Pharmaceutical Co., Ltd
Active, not recruiting - verified February 2017

IVUS Assessment of Atheroma Burden After Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   University Hospital, Toulouse
Recruiting - verified February 2017

Assessment With CCTA and MRI in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myocardial Scar in Subclinical Coronary Atherosclerosis

Conditions:   Type 2 Diabetes Mellitus;   Coronary Atherosclerosis
Intervention:   Drug: Iobitridol
Sponsor:   Guerbet
Active, not recruiting - verified February 2017

Effect of Exercise Before Gastric Bypass

Condition:   Morbid Obesity
Intervention:   Behavioral: High intensity exercise
Sponsor:   Norwegian University of Science and Technology
Completed - verified February 2017

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Darapladib 160 mg;   Drug: Placebo;   Other: Standard Therapy
Sponsors:   GlaxoSmithKline;   The TIMI Study Group
Completed - verified February 2017

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Condition:   Human Immunodeficiency Virus
Interventions:   Drug: Maraviroc along with an optimized background antiretroviral drug regimen;   Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsors:   ViiV Healthcare;   Pfizer
Active, not recruiting - verified February 2017

An Observational Study of TNKase in Patients Enrolled in the National Registry of Myocardial Infarction 4 and 5 (POST)

Condition:   Acute Myocardial Infarction
Intervention:  
Sponsor:   Genentech, Inc.
Completed - verified February 2017

Diagnostic Utility of Contrast Echocardiography for Detection of LV Thrombi Post ST Elevation Myocardial Infarction

Conditions:   Thrombus;   Myocardial Infarction
Intervention:  
Sponsors:   Weill Medical College of Cornell University;   Lantheus Medical Imaging
Recruiting - verified February 2017

Determinants of Cardiac Risk Factor Modification in Latinos With Coronary Artery Disease

Condition:   Coronary Artery Disease
Intervention:  
Sponsors:   Weill Medical College of Cornell University;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified February 2017

A Randomized Trial: Changing Behavior in Post-Angioplasty Patients

Condition:   Angioplasty Patients
Intervention:   Behavioral: Intervention Group
Sponsor:   Weill Medical College of Cornell University
Completed - verified February 2017

Vascular Aging: The Link That Bridges Age to Atherosclerosis (The VALIDATE Study)

Conditions:   Atherosclerosis;   Cardiovascular Disease;   Vascular Diseases
Intervention:  
Sponsor:   National Institute on Aging (NIA)
Active, not recruiting - verified January 26, 2017

Exercise-training Before Coronary Artery Bypass Graft (CABG)

Conditions:   Angina;   Coronary Artery Disease
Intervention:   Behavioral: Exercise training
Sponsor:   Norwegian University of Science and Technology
Completed - verified February 2017

Clinical and Economic Consequences of Left Atrial Bipolar Radiofrequency Ablation of Persistent and Permanent Atrial Fibrillation During Cardiac Surgery

Conditions:   Atrial Fibrillation;   Coronary Artery Disease
Intervention:   Procedure: bipolar radiofrequency ablation of persistent and permanent AF
Sponsors:   Medtronic Bakken Research Center;   Medtronic
Terminated - verified February 2017

Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)

Condition:   Coronary Artery Disease
Intervention:   Drug: pexelizumab in conjunction with CABG
Sponsors:   Alexion Pharmaceuticals;   Procter and Gamble
Active, not recruiting - verified February 2017

Women's Health Trial: Feasibility Study in Minority Populations

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Heart Diseases;   Myocardial Ischemia;   Postmenopause
Intervention:   Behavioral: diet, fat-restricted
Sponsors:   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified February 2017